



## *News Release*

Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc., 508-359-4005, x108

### Interventional cardiologists at *TCT 2009* assert greater clinical precision and enhanced patient outcomes in the cath lab using vascular robotic technology for PCI

NATICK, Mass., Oct. 5, 2009—**Corindus Vascular Robotics**, an emerging medical technology company focused on vascular robotic systems for the cath lab, announced today that three leading interventional cardiologists who spoke at a Company-hosted breakfast symposium during the 2009 annual meeting of the Transcatheter Cardiovascular Therapeutics (“TCT”) described how the **CorPath™** System may revolutionize percutaneous coronary intervention (PCI) procedures. Corindus expects to seek regulatory clearances for the initial application of the CorPath vascular robotic system: PCI.

The event—“The CorPath Vascular Robotic System: A New Standard in Precision PCI,” moderated by Dr. Peter Fitzgerald, Director, Center for Cardiovascular Technology, Stanford University Medical Center—focused on advancements in vascular robotics and the resulting impact of precision and clinical productivity during PCI procedures. The speakers described how CorPath enables them to more accurately deliver and deploy therapeutic devices, such as stents and balloon catheters, and provide more control in guidewire delivery.

“Percutaneous valve procedures require greater control and accuracy than other PCI procedures, as well as real-time access to multi-modality imaging,” explained **Jeffery Popma, M.D., Associate Professor of Medicine and Director of Innovations in Interventional Cardiology at Beth Israel Deaconess Medical Center (BIDMC)** and Associate Director for TCT 2009. Dr. Popma also shared his vision for using vascular robotics during procedures to repair structural heart defects, specifically aortic valve replacement. “A robotic PCI system, such as the CorPath system, has the potential to provide clinical advantages by enabling real-time measurement capabilities and the accurate placement of the valve.”

“The CorPath System will help clinicians improve patient outcomes for everyday PCI procedures,” added **Giora Weisz, M.D., Director of Clinical Research for the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center**, and Associate Director for TCT 2009. “This robotic system can accurately place a stent to within one millimeter of the intended destination. As a result, I can potentially reduce the incidence of placing a second stent in a patient and improve long-term outcomes. I believe the CorPath System elevates the standard of care in the cath lab and improves patient safety during vascular procedures.”

(more)

“Vascular robotics is practical for large teaching centers and also community hospitals, as it provides benefits to everyday PCI procedures for the patient, the hospital *and* the physician,” said **Joseph P. Carrozza, Jr., M.D., Chief of Cardiovascular Medicine at St. Elizabeth’s Medical Center (Boston)**. “The CorPath System is the next game-changing technology for the cath lab.”

“The cath lab is a *hazardous* work environment for physicians,” said **David M. Handler, President and CEO of Corindus**. “Our CorPath system is designed to significantly reduce radiation exposure, physician fatigue and other occupational hazards to physicians by allowing him or her to operate in an ergonomically correct position while shielded from harmful and repeated radiation exposure,” added Handler.

*Percutaneous coronary intervention* (PCI), commonly known as ‘coronary angioplasty’ or simply ‘angioplasty’, is a procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist in a cath lab utilizing x-ray angiography imaging—which exposes physicians to significant occupational hazards, including radiation as well as chronic orthopedic ailments and fatigue due to the required use of heavy lead-protection garments.

#### **About Corindus Vascular Robotics**

Corindus designs, manufactures and commercializes precision vascular robotic systems for use in minimally invasive procedures. The Company’s disposable medical device business model is enabled by a simple and low-cost console. The Company’s initial product, the **CorPath™** system, is the world’s first to precisely drive coronary guidewires and stent/balloon catheters during percutaneous coronary intervention (PCI) procedures performed in a cath lab. While Corindus is focused initially on PCIs, its open-platform technology and IP allow the Company to address other segments of the vascular market—including peripheral and other complex cardiac interventions such as structural heart disease repair.

#####

NOTE: The Corindus *CorPath™* system is not cleared for use in the U.S. by the Food and Drug Administration (FDA). It remains investigational in the U.S.